Business
Update on Acquisition of Oncogeni and Placing
Update on Acquisition of Oncogeni and Placing.
About this update from Coiled Therapeutics Plc
[{"type":"text","content":"\n \n \n 23 June 2022\n \n \n \n \n \n \n \n \n \n \n \n \n \n Roquefort Therapeutics plc\n \n \n \n \n (\"Roquefort Therapeutics\" or the \"Company\")\n \n \n \n \n \n \n \n \n \n Update on Acquisition of Oncogeni Limited and Placing\n \n \n \n \n \n \n \n \n Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company focused on early-stage opportunities in the biotechnology sector, is pleased to announce that it has published a corporate presentation with respect to the proposed acquisition of Oncogeni Limited and the proposed Placing, as announced by the Company on 22 June 2022. A copy of the presentation is available on the Company's website at\n \n https://www.roquefortplc.com/category/presentations/\n \n \n \n \n \n \n The Company looks forward to providing further updates in relation to the acquisition of Oncogeni Limited and the Placing as and when appropriate.\n \n \n \n \n \n Enquiries:\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Roquefort Therapeutics plc\n \n \n \n \n \n \n \n Stephen West (Chairman)\n \n \n \n \n +44 (0)20 3290 9339\n \n \n \n \n \n \n \n \n \n \n Buchanan (Public Relations)\n \n \n \n Ben Romney / Jamie Hooper / George Beale\n \n \n \n \n \n \n \n \n Optiva Securities Limited (Broker)\n \n \n \n \n \n \n \n \n +44 (0)20 7466 5000\n \n \n \n \n \n \n Christian Dennis\n \n \n \n \n +44 (0)20 3411 1881\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n For further information on Roquefort Therapeutics, please visit\n \n www.roquefortplc.com\n \n and @RoquefortTherap on Twitter.\n \n \n \n \n \n LEI: 254900P4SISIWOR9RH34\n \n \n \n \n \n \n \n \n About Roquefort Therapeutics\n \n \n \n \n \n \n Roquefort Therapeutics (LSE:ROQ) is a Main Market listed biotech company developing products through the pre-clinical phase prior to partnering or selling to big pharma. The Company is a pre-clinical biotech company focused on developing first in class Midkine targeting drugs for the treatment of cancer.\n \n \n \n \n \n Through extensive research resulting in validation through publication in over 1,000 scientific journals, Roquefort Therapeutics has identified the potential to exploit the broad therapeutic potential of Midkine for a number of clinical indications of unmet needs. Roquefort Therapeu...